<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01825213</url>
  </required_header>
  <id_info>
    <org_study_id>2013P000042</org_study_id>
    <nct_id>NCT01825213</nct_id>
  </id_info>
  <brief_title>Stratification of Patients With Chronic Liver Disease Using Multi Spectral CT</brief_title>
  <official_title>Stratification of Patients With Chronic Liver Disease Using Multi Spectral CT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the feasibility to stratify liver fibrosis in
      patients with chronic liver disease through non-invasive, spectral CT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a retrospective study, in which a FDA approved imaging device (spectral CT scanner)
      currently used for several clinical applications will be evaluated for feasibility of
      studying chronic liver disease (this application has not yet been validated).

      Tomographic imaging has assumed a fundamental role in patients with Chronic Liver Disease
      (CLD) to screen patients for hepatocellular carcinoma (HCC), and, is increasingly being
      explored as a noninvasive alternative for characterizing liver fibrosis. The overarching goal
      of this study is to improve noninvasive characterization of liver fibrosis through spectral
      CT.

      Hypothesis: concentration of iodine-based contrast agent in the liver parenchyma during the
      delayed phase, as measured with spectral CT imaging, increases monotonically with Ishak
      fibrosis score obtained from liver biopsy. This hypothesis is supported by the literature and
      our preliminary data, described in the references section (Lamb et al. 2015).

      We will evaluate multiphase spectral CT images consisting of the arterial phase, 2-minute
      delayed phase, and 5-minute delayed phase. Fibrosis will be assessed on both delayed phase
      images, where it is assumed that any remaining contrast agent, in the liver, is due to the
      presence of fibrosis. This type of multiphase protocol can still be used to image CLD
      patients with spectral CT for HCC detection and, thus, will not interfere with liver lesion
      workup and evaluation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of hepatocellular carcinoma on Multi Spectral CT</measure>
    <time_frame>confirmation with focal biopsy and or/contrast-enhanced MRI of the liver acquired within 6 months prior to the multi spectral CT scan.</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">10</enrollment>
  <condition>Chronic Liver Disease</condition>
  <condition>HepatoCellular Carcinoma</condition>
  <condition>Liver Fibrosis</condition>
  <arm_group>
    <arm_group_label>Multispectral CT of the liver</arm_group_label>
    <description>Images of lesions and liver will be compared to histology.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Multispectral CT of the liver</intervention_name>
    <description>Analysis of the background liver and liver lesions will be performed on Multi Spectral CT images and compared to histology.</description>
    <arm_group_label>Multispectral CT of the liver</arm_group_label>
    <other_name>Discovery CT 750 HD, K120833</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        adult patients with newly stablished diagnosis of hepatocellular carcinoma complying with
        selection criteria for liver transplantation and/or biopsy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patient with chronic liver disease undergoing CT scan for/suspicion of
             hepatocellular carcinoma.

          -  Patients should be scheduled for/or should have obtained a multiphasic MRI of the
             liver.

        Exclusion Criteria:

          -  Patients &lt; 18 years old.

          -  History of allergy to intravenous contrast.

          -  Patients at risk for contrast-induced-nephropathy,

          -  Pregnant patients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dushyant V Sahani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director of CT, Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital,</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Wang G, Butler A, Yu H, Campbell M. Guest editorial. Special issue on spectral CT. IEEE Trans Med Imaging. 2015 Mar;34(3):693-6.</citation>
    <PMID>25893236</PMID>
  </reference>
  <reference>
    <citation>Zhao W, Niu T, Xing L, Xie Y, Xiong G, Elmore K, Zhu J, Wang L, Min JK. Using edge-preserving algorithm with non-local mean for significantly improved image-domain material decomposition in dual-energy CT. Phys Med Biol. 2016 Feb 7;61(3):1332-51.</citation>
    <PMID>26796948</PMID>
  </reference>
  <reference>
    <citation>Breguet R, Ronot M, Goossens N, Hansen C, Giostra E, Majno P, Becker CD, Spahr L, Terraz S. Liver volume is a prognostic indicator for clinical outcome of patients with alcoholic hepatitis. Abdom Radiol (NY). 2017 Feb;42(2):460-467. doi: 10.1007/s00261-016-0892-7.</citation>
    <PMID>27604894</PMID>
  </reference>
  <reference>
    <citation>Lestra T, Mul√© S, Millet I, Carsin-Vu A, Taourel P, Hoeffel C. Applications of dual energy computed tomography in abdominal imaging. Diagn Interv Imaging. 2016 Jun;97(6):593-603. doi: 10.1016/j.diii.2015.11.018. Epub 2016 Mar 15. Review.</citation>
    <PMID>26993967</PMID>
  </reference>
  <reference>
    <citation>Patino M, Prochowski A, Agrawal MD, Simeone FJ, Gupta R, Hahn PF, Sahani DV. Material Separation Using Dual-Energy CT: Current and Emerging Applications. Radiographics. 2016 Jul-Aug;36(4):1087-105. doi: 10.1148/rg.2016150220. Review.</citation>
    <PMID>27399237</PMID>
  </reference>
  <reference>
    <citation>Daginawala N, Li B, Buch K, Yu H, Tischler B, Qureshi MM, Soto JA, Anderson S. Using texture analyses of contrast enhanced CT to assess hepatic fibrosis. Eur J Radiol. 2016 Mar;85(3):511-7. doi: 10.1016/j.ejrad.2015.12.009. Epub 2015 Dec 17.</citation>
    <PMID>26860661</PMID>
  </reference>
  <reference>
    <citation>De Cecco CN, Boll DT, Bolus DN, Foley WD, Kaza RK, Morgan DE, Rofsky NM, Sahani DV, Schoepf UJ, Shuman WP, Siegel MJ, Vrtiska TJ, Yeh BM, Berland LL. White Paper of the Society of Computed Body Tomography and Magnetic Resonance on Dual-Energy CT, Part 4: Abdominal and Pelvic Applications. J Comput Assist Tomogr. 2017 Jan;41(1):8-14. doi: 10.1097/RCT.0000000000000546.</citation>
    <PMID>27824670</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2013</study_first_submitted>
  <study_first_submitted_qc>April 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2013</study_first_posted>
  <last_update_submitted>April 13, 2017</last_update_submitted>
  <last_update_submitted_qc>April 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Dushyant V. Sahani</investigator_full_name>
    <investigator_title>Director of CT, Associate Professor of Radiology Harvard Medical School</investigator_title>
  </responsible_party>
  <keyword>Liver disease</keyword>
  <keyword>Multi Spectral CT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Extracts</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>PMID: 25181365</doc_id>
      <doc_type>Peer reviewed article</doc_type>
      <doc_url>http://ieeexplore.ieee.org/document/6887313/?arnumber=6887313</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

